Перегляд за Автор "Mehta, Aashna"
Зараз показуємо 1 - 3 з 3
Результатів на сторінці
Налаштування сортування
Документ Immunological and inflammatory effects of infectious diseases in circadian rhythm disruption and future therapeutic directions(Springer, 2023-01-19) Huang, Helen; Mehta, Aashna; Jacob, Kalmanovich; Anand, Ayush; Bejarano, Maria Chilo; Garg, Tulika; Khan, Nida; Тonpouwo, Gauvain Kankeu; Shkodina, Anastasiia D.; Bardhan, Mainak; Шкодіна, Анастасія ДмитрівнаBackground Circadian rhythm is characterised by daily variations in biological activity to align with the light and dark cycle. These diurnal variations, in turn, influence physiological functions such as blood pressure, temperature, and sleep–wake cycle. Though it is well established that the circadian pathway is linked to pro-inflammatory responses and circulating immune cells, its association with infectious diseases is widely unknown. Objective This comprehensive review aims to describe the association between circadian rhythm and host immune response to various kinds of infection. Methods We conducted a literature search in databases Pubmed/Medline and Science direct. Our paper includes a comprehensive analysis of findings from articles in English which was related to our hypothesis. Findings Molecular clocks determine circadian rhythm disruption in response to infection, influencing the host’s response toward infection. Moreover, there is a complex interplay with intrinsic oscillators of pathogens and the influence of specific infectious processes on the CLOCK: BMAL1 pathway. Such mechanisms vary for bacterial and viral infections, both well studied in the literature. However, less is known about the association of parasitic infections and fungal pathogens with circadian rhythm modulation. Conclusion It is shown that bidirectional relationships exist between circadian rhythm disruption and infectious process, which contains interplay between the host’s and pathogens’ circadian oscillator, immune response, and the influence of specific infectious. Further studies exploring the modulations of circadian rhythm and immunity can offer novel explanations of different susceptibilities to infection and can lead to therapeutic avenues in circadian immune modulation of infectious diseases.Документ Schizophrenia and disruption of circadian rhythms: An overview of genetic, metabolic and clinical signs(Elsevier, 2024) Boiko, D. I.; Chopra, Hitesh; Bilal, Muhammad; Kydon, P. V.; Herasymenko, L. O.; Rud, V. O.; Bodnar, L. A.; Vasylyeva, G. Yu.; Isakov, R. I.; Zhyvotovska, L. V.; Mehta, Aashna; Skrypnikov, A. M.; Бойко, Дмитро Іванович; Кидонь, Павло Володимирович; Герасименко, Лариса Олександрівна; Рудь, Вадим Олексійович; Боднар, Леся Анатоліївна; Васильєва, Ганна Юріївна; Ісаков, Рустам Ісроїлович; Животовська, Лілія Валентинівна; Скрипніков, Андрій МиколайовичA molecular clock in the suprachiasmatic nucleus of the anterior hypothalamus, which is entrained by the dark-light cycle and controls the sleep-wake cycle, regulates circadian rhythms. The risk of developing mental disorders, such as schizophrenia, has long been linked to sleep abnormalities. Additionally, a common aspect of mental disorders is sleep disturbance, which has a direct impact on the intensity of the symptoms and the quality of life of the patient. This relationship can be explained by gene alterations such as CLOCK in schizophrenia which are also important components of the physiological circadian rhythm. The function of dopamine and adenosine in circadian rhythm should also be noted, as these hypotheses are considered to be the most popular theories explaining schizophrenia pathogenesis. Therefore, determining the presence of a causal link between the two can be key to identifying new potential targets in schizophrenia therapy, which can open new avenues for clinical research as well as psychiatric care. We review circadian disruption in schizophrenia at the genetic, metabolic, and clinical levels. We summarize data about clock and clock-controlled genes' alterations, neurotransmitter systems' impairments, and association with chronotype in schizophrenia patients. Our findings demonstrate that in schizophrenia either homeostatic or circadian processes of sleep regulation are disturbed. Also, we found an insufficient number of studies aimed at studying the relationship between known biological phenomena of circadian disorders and clinical signs of schizophrenia.Документ Targeting oxidative stress mechanisms to treat Alzheimer's and Parkinson's disease: a critical review(Hindawi, 2022) Aborode, Abdullahi Tunde; Pustake, Manas; Awuah, Wireko Andrew; Alwerdani, Mariam; Shah, Parth; Yarlagadda, Rohan; Ahmad, Shahzaib; Correia, Inês F. Silva; Chandra, Ayush; Nansubug, Esther Patience; Abdul-Rahman, Toufik; Mehta, Aashna; Ali, Omar; Amaka, Shekinah Obinna; Zuñiga, Yves Miel H.; Shkodina, A. D.; Inya, Oko Christian; Shen, Bairong; Alexiou, Athanasios; Шкодіна, Анастасія ДмитрівнаNeurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) are becoming more frequent as the age increases. Contemporary therapies provide symptom resolution instead of targeting underlying pathological pathways. Consequently, there is considerable heterogeneity in response to treatment. Research has elucidated multiple potential of pathophysiological mechanisms contributing to neurodegenerative conditions, among which oxidative stress pathways appear to be suitable drug targets. The oxidative stress pathway has given rise to numerous novel pharmacological therapies that may provide a new avenue for neurodegenerative diseases. For example, SKQ (plastoquinone), MitoVitE, vitamin E, SOD mimic, MitoTEMPO (SOD mimetic), and bioactive molecules like curcumin and vitamin C have indeed been examined. To better understand how oxidative stress contributes to neurodegenerative diseases (such as Alzheimer’s and Parkinson’s), we analyzed the medicinal qualities of medicines that target markers in the cellular oxidative pathways. The specific pathway by which mitochondrial dysfunction causes neurodegeneration will require more investigation. An animal study should be carried out on medications that tackle cellular redox mechanisms but are not currently licensed for use in the management of neurodegenerative conditions.